J. Armitage

Surgery · The Lancet · 2003–2018

A researcher in the Science corpus: 12 papers; trusts 4 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Surgery — 124 citations into it; #376 of 1,106 by trust here, #38 by citations
• Endocrinology, Diabetes and Metabolism — 79 citations into it; #255 of 623 by trust here, #73 by citations
• Cancer Research — 37 citations into it
• Molecular Biology — 21 citations into it
• Radiology, Nuclear Medicine and Imaging — 17 citations into it
• Public Health, Environmental and Occupational Health — 16 citations into it

Whom J. Armitage trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. AndrewJ. S. Coats
2. G. Moneta
3. J. Tobert
4. R. Collins
5. M. Law
6. B. J. Gersh

Who trusts J. Armitage overall

1. Massimo F. Piepoli
2. V. Basevi
3. D. Avers
4. R. Collins

Papers from J. Armitage's perspective

Ordered by how strongly the researchers J. Armitage trusts endorse each paper. Same corpus, a different order for every researcher.

1. Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (Journal of the American Pharmacists Association)
2. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials (The Lancet)
3. Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention (The Lancet)
4. The safety of statins in clinical practice. (The Lancet)
5. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. (The Lancet)
6. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study (Cardiovascular Drugs and Therapy)
7. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial… (European Heart Journal)
8. When are randomised trials unnecessary? Picking signal from noise (British medical journal)
9. Bias and causal associations in observational research.
10. Use of statins and the risk of death in patients with prostate cancer. (Journal of Clinical Oncology)

Their papers

• Interpretation of the evidence for the efficacy and safety of statin therapy. (2016) — 1,672 citations
• Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus (2018) — 969 citations
• Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus (2018) — 597 citations
• Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. (2016) — 1,223 citations
• Effects of extended-release niacin with laropiprant in high-risk patients. (2014) — 1,436 citations
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013) — 661 citations
• A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease (2011) — 669 citations
• SLCO1B1 variants and statin-induced myopathy--a genomewide study. (2008) — 2,015 citations
• Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. (2008) — 1,960 citations
• The safety of statins in clinical practice. (2007) — 814 citations
• Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. (2004) — 1,092 citations
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. (2003) — 2,873 citations